Insulin
Insulin
Insulin secretion, mechanism of action, preparations, classification, uses and adverse effects
Introduction to Insulin
Pancreatic Hormones
- Alpha cells: Secrete glucagon, which increases blood glucose.
- Beta cells: Secrete insulin, which decreases blood glucose.
- Delta cells: Secrete somatostatin.
- PP cells: Secrete pancreatic polypeptide.
Diabetes Mellitus
Diabetes mellitus is a metabolic disorder characterised by persistent elevation of blood glucose due to insufficient insulin secretion, insulin resistance or both. It affects carbohydrate, fat and protein metabolism.
- Fasting plasma glucose: 126 mg/dL or higher.
- Two-hour glucose after a 75 g oral glucose tolerance test: 200 mg/dL or higher.
- HbA1c: 6.5% or higher.
- Random plasma glucose: 200 mg/dL or higher with classic symptoms of hyperglycaemia.
Types of Diabetes
- Type 1: Destruction of pancreatic beta cells causes severe insulin deficiency. Insulin treatment is essential and patients are more prone to ketoacidosis.
- Type 2: Insulin resistance with progressive beta-cell dysfunction. It is commonly associated with genetic and lifestyle factors.
- Other specific types: Due to pancreatic diseases, genetic conditions or drugs.
- Gestational diabetes: Diabetes first recognised during pregnancy.
Insulin Secretion
Mechanism of Insulin Release
- Glucose enters the pancreatic beta cell through glucose transporters.
- Glucose is metabolised, increasing intracellular ATP.
- ATP closes ATP-sensitive potassium channels.
- Potassium movement decreases, causing membrane depolarisation.
- Voltage-gated calcium channels open.
- Calcium enters the cell and stimulates exocytosis of insulin-containing granules.
- Insulin is released into the bloodstream.
Insulin Structure and Production
- Insulin is initially synthesised as preproinsulin.
- Removal of the signal peptide produces proinsulin.
- Removal of the connecting C-peptide produces mature insulin.
- Mature insulin contains two chains connected by disulphide bonds.
- The A chain has 21 amino acids and the B chain has 30 amino acids.
Production of Human Insulin
Recombinant DNA technology is used to produce human insulin. The human insulin gene is introduced into microorganisms such as E. coli or yeast, which produce insulin that can be purified for therapeutic use.
Mechanism and Actions of Insulin
Mechanism of Action
- Insulin binds to the alpha subunit of its receptor.
- The beta subunit activates tyrosine kinase.
- Tyrosine phosphorylation activates insulin receptor substrates (IRS).
- Downstream signalling promotes movement of GLUT-4 transporters to the cell membrane.
- Glucose enters cells and is utilised or stored.
Actions on Different Tissues
Effects of Insulin Deficiency
- Reduced glucose uptake by peripheral tissues.
- Increased hepatic glucose production.
- Increased protein breakdown and gluconeogenesis.
- Increased lipolysis and free fatty acids.
- Increased ketone body production, particularly in type 1 diabetes.
Insulin Preparations and Classification
Modern insulin preparations include recombinant human insulin and insulin analogues. Analogues are modified to produce faster or longer-lasting effects.
Rapid and Ultra-Rapid Acting
- Lispro
- Aspart
- Glulisine
These act rapidly and are used to control the rise in blood glucose after meals.
Short Acting
- Regular human insulin: Short-acting soluble insulin.
- Can be administered intravenously in appropriate emergency settings.
- Usually administered before meals when used subcutaneously.
Intermediate Acting
- NPH insulin: Neutral Protamine Hagedorn insulin.
- Lente preparations: Zinc-containing insulin suspensions.
These provide longer action than regular insulin and can help maintain insulin levels between meals and overnight.
Long and Ultra-Long Acting
- Glargine: Long-acting basal insulin.
- Detemir: Long-acting insulin analogue.
- Degludec: Ultra-long-acting insulin.
- Rapid-acting examples: Lispro, aspart and glulisine.
- Regular insulin: Important short-acting preparation used intravenously in emergencies.
- NPH: Intermediate-acting insulin.
- Glargine: Acidic formulation; should not be mixed with other insulin preparations.
- Degludec: Ultra-long-acting insulin.
Methods of Administration
- Conventional insulin syringes.
- Prefilled insulin pens and cartridges.
- Continuous subcutaneous insulin infusion pumps.
- Inhaled insulin preparations are available in selected settings.
Absorption is generally fastest from the abdomen, followed by the arm and then the thigh, although the rate varies with preparation and injection technique.
Therapeutic Uses
- Type 1 diabetes mellitus: Essential lifelong replacement therapy.
- Type 2 diabetes mellitus: Used when oral medicines and other treatments do not provide adequate control or when insulin is otherwise indicated.
- Gestational diabetes: Used when glucose control cannot be achieved with appropriate non-insulin measures.
- Diabetic ketoacidosis: Regular insulin is used in hospital-based treatment.
- Hyperosmolar hyperglycaemic state: Insulin is used along with fluid and electrolyte correction.
- Perioperative management: Used when precise blood glucose control is required during surgery or serious illness.
- Severe hyperglycaemia: May be needed during infection, trauma or other acute stress.
Adverse Effects and Drug Interactions
Hypoglycaemia
Causes
- Missing or delaying meals after insulin administration.
- Excessive insulin dose.
- Unexpected physical exercise.
- Renal impairment and reduced insulin clearance.
- Increased sensitivity to insulin.
Signs and Symptoms
- Early symptoms: Sweating, tremors, hunger, anxiety, palpitations and tingling.
- Neurological symptoms: Confusion, difficulty concentrating, dizziness, drowsiness and behavioural changes.
- Severe hypoglycaemia: Seizures and unconsciousness.
Other Adverse Effects
- Lipodystrophy: Lipohypertrophy or lipoatrophy at injection sites. Rotation of injection sites helps prevent it.
- Weight gain: May occur during insulin treatment.
- Oedema: Can occur in some patients.
- Allergic reactions: Less common with modern human insulin preparations.
- Insulin resistance: May occur due to reduced receptor number or sensitivity and other factors.
- Local reactions: Pain, redness or irritation at injection sites.
Drug Interactions
- Beta blockers: Can mask warning signs such as tremors and palpitations and may prolong hypoglycaemia.
- Corticosteroids: Can increase blood glucose and insulin requirements.
- Thiazide and loop diuretics: May worsen glycaemic control.
- Alcohol: Can increase the risk of hypoglycaemia, especially when food intake is inadequate.
- High-dose salicylates: May enhance glucose-lowering effects.